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Abstract
Background:  Multiple Myeloma (MM) is a B cell neoplasm characterized by the clonal
proliferation of plasma cells. Skeletal complications are found in up to 80% of myeloma patients at
presentation and are major cause of morbidity.
Methods: 49 patients were enrolled with MM admitted to Black Sea Technical University Hospital
between 2002–2005. Pathologic fractures (PFs) were determined and the patients with or without
PF were followed up minumum 3 years for survival analysis.
Results: PF was observed in 24 patients (49%) and not observed in 25 patients (51%). The risk of
death was increased in the patients with PF compared with patients who had no fractures. While
overall survival was 17.6 months in the patients with PFs, it was 57.3 months in the patients with
no PFs.
Conclusion: These findings suggest that PFs may induce reduced survival and increased mortality
in the MM patients, however, larger sample size is essential to draw clearer conclusions added to
these data.
Background
MM is a B cell neoplasm characterized by the clonal pro-
liferation of plasma cells within the bone marrow. Skele-
tal complications including enhanced bone loss
associated with diffuse osteopenia, focal lytic lesions, PFs,
hypercalcemia, and bone pain are found in up to 80% of
myeloma patients at presentation and are major causes of
morbidity. Increased osteoclastic activity combined with
inhibited osteoblastic activity contribute to the skeletal
complications. The increased bone turnover has been
characterized as an important facilitator of proliferation
and tumor cell survival in MM [1-3].
PFs are important healthcare concern in patients with
MM. They may cause severe bone pain, limit mobility,
and require surgery and hospitalization for treatment.
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Thus, fractures can interfere with functional independ-
ence and may shorten survival. Although a relationship
between PFs and survival in patients with MM has been
reported with clinical observations, there are limited data
on correlation pattern [4].
In the present study, we planned to determine the impact
of PFs on survival in patients with MM.
Methods
49 patients were enrolled with MM admitted to Black Sea
Technical University Hospital between 2002–2005. All
patients had myeloma diagnosis and treatment criteria.
PFs were determined with radiography, scintigraphy, and
Magnetic Resonance Imaging (MRI), if radiography is
insufficient for diagnosis or patients having no visuable
lesions in the radiography are symptomatic. Treatment
was begun to all patients and continued to provide remis-
sion and plateau phase. Treatment options including mel-
phalan, prednisolone, vincristine, dexamethasone,
adriamycine, cyclophosphamide, thalidomide, borte-
zomib, bisphosphonates, autologous transplantation
were planned case by case. Due to myeloma treatment
guideline, treatment modalities were arranged as first, sec-
ond, and third line. Melphalan-Prednisolone (MP) and
Vincristine-Adriamycine-Dexamethasone (VAD) were
planned as first line treatment; other regimens were
planned as second and third line. The patients with or
without PF were followed up minumum 3 years for sur-
vival analysis.
Statistical Analysis
Survival was studied from the date of diagnosis to the last
contact with the patient. Survival curves were calculated
using the Kaplan-Meier method and statistical compari-
sons were performed by the log-rank test. The relationship
between predictor factors and survival was examined
using Cox's regression analysis. Quantitative data were
analysed using the chi-square tests. P values <0.05 were
considered to be significant.
Results
Of the 49 patients, 29 were male and 20 were female. The
mean age was 63.3 ± 11.6 (min-max, 40–80). 19 patients
were Immunoglobuline (Ig) G, 16 patients were IgA, 7
patients were light chain, and 7 patients were nonsecre-
tory type. 36 patients were stage 3, 10 patients were stage
2, and 3 patients were stage 1 according to Durie-Salmon
classification. The laboratory values of the patients are
presented in Table 1. 41 patients (83.7%) had lytic lesions
and 8 patients (16.3%) had no lytic lesions. PF was
observed in 24 patients (49%) and not observed in 25
patients (51%). PFs were defined vertebral and nonverte-
bral. 17 patients had vertebral fractures and 7 patients had
fractures in other sides including femur, humerus, ribs,
and bisphosphonate therapy was administered to all
patients with both zoledronic acid and pamidronate. 9
patients required surgical treatment and 10 patients
required radiotherapy. Response to first line treatment
was determined in 19% of the patients with PF. The risk
of death was increased in the patients with PF compared
with patients who had no fractures (p = 0.03). While over-
all survival was 17.6 months in the patients with PF, it was
57.3 months in the patients with no PF (according to Kap-
lan Meire test, log rank p = 0.03) (Figure 1). In the Cox
regresion analysis, PFs were a significant predictor of
decreased survival (OR: 2.62; 95% CI:1.12–6.10, p =
0.02). The effect on survival is independent compared to
other prognostic parameters including hemoglobin, cal-
cium, stage, albumine, α2  microglobulin, and lytic
lesions.
Discussion
PFs occur in approximately 40% of patients with multiple
myeloma [5]. More recent studies with the addition of
MRI assessment show a much higher proportion of
patients actually have fractures at presentation [6]. PFs
result not only from the direct deposits of myeloma cells
within the bone, but also from the release of soluble fac-
tors by both the tumor and the bone microenvironment,
resulting in the stimulation of osteoclast activity and bone
resorption [7]. Osteoclast-activating factors (OAFs) and
Overall survival in patients with MM Figure 1
Overall survival in patients with MM.
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Table 1: Laboratory parametes of patients
n = 49 Mean Minimum-Maximum
Hb (g/dL) 9.08 ± 2.18 5–13.3
Creatinine (g/dL) 1.9 ± 1.6 0.5–6.6
B2 microglobulin (mg/dL) 1.54 ± 1.93 0.2–7.7
LDH (U/L) 416.9 ± 226.2 112–1378
Albumin (g/dL) 3.2 ± 0.76 1.8–5.1
Calcium (mg/dL) 10.36 ± 1.89 7.7–15.3Journal of Experimental & Clinical Cancer Research 2008, 27:11 http://www.jeccr.com/content/27/1/11
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receptor activator of nuclear factor-κB (RANK) ligand
(RANKL)-osteoprotegerin-RANK system have provided a
better understanding of myeloma bone disease in molec-
ular level. Myeloma cells adhere to the stromal cells and
induce secretion of OAFs including interleukin (IL)-6, IL-
1, tumor necrosis factor (TNF), IL-11, macrophage inflam-
matory protein-1α (MIP-1α), hepatocyte growth factor
(HGF), parathyroid hormone-related peptide (PTHrP),
and others. OAFs increase expression of RANKL on the
marrow stromal cell surface. RANKL binds to the RANK
receptor on osteoclast precursors and triggers osteoclast
differentiation and activation. This interplay among the
activated osteoclast, stromal cells and OAFs in the bone
marrow microenvironment, in turn, stimulates MM cells
growth. The activity of RANKL can be blocked by osteo-
protegerin, preventing the interaction between RANK and
RANKL. Also, inhibition of osteoblast activity plays a role
in the pathogenesis of MM bone disease. Dickkopf
(DKK)-1, an inhibitor of Wnt signaling secreted by MM
cells, causes a hindered osteoblast differentiation and
activity. In addition to this mechanism, malignant plasma
cells are able to induce osteoblast apoptosis [8-10].
PFs have been associated with a 23–32% increased risk of
mortality in prostate cancer, breast cancer, and MM [11].
Several factors may affect the situation: for example, loss
of mobility and functional independence, increased risk
of deep vein thrombosis, surgery for fracture, and biologic
behavior of disease. In the recently published metaanaly-
sis, it was concluded that PFs correlate with reduced sur-
vival in patients with malignant bone disease [4]. Our
study similar to this metaanalysis, showed that MM
patients with PF have reduced survival and increased mor-
tality probably with biologic behavior of MM. Because, no
relationship between PFs and other activity parameters of
MM was observed. It is an independent factor for survival
and may be related to the pathogenesis of bone disease. As
viewed in the literature, use of bisphosphonates, which
involves the inhibition of osteoclast-mediated bone
resorption, is together with demonstrated improved sur-
vival and reduced PFs. A decreasing marker of bone
resorption, N-telopeptide of type I collagen, in the bone
metastases patients, treated with zoledronic acid, associ-
ated with increased overall survival [11-13]. All data have
showed that myeloma bone disease has a different effect
in the prognosis of MM.
The most common site of fractures is in the spine (55%–
70%) especially in the lower thoracic or lumber vertabral
bodies. Vertebral compression fractures had increased
nearly a three-fold compared to a healthy person [3,14].
In our patients, vertebral fractures frequency were higher
compared to other fracture sides. Older individuals with
vertebral fractures have an increased risk of mortality.
Kado et al. reported that women with vertebral fractures
had an age-adjusted 32% increased risk of mortality com-
pared with women without incident vertebral fractures
[15]. As a whole, vertebral fractures independently plus
MM-related vertebral fracture incidence contribute to the
higher morbidity rate in MM patients.
Conclusion
These findings suggest that PFs may cause reduced sur-
vival and increased mortality in the MM patients, how-
ever, larger sample size is essential to draw clearer
conclusions added to these data.
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